アブストラクト
| Title | 肺がん |
|---|---|
| Subtitle | 特集2 免疫チェックポイント阻害薬の使い方 & irAE対策 臓器別にみるICIの使い方 |
| Authors | 各務博 |
| Authors (kana) | |
| Organization | 埼玉医科大学国際医療センター呼吸器内科 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 6 |
| Page | 1111-1115 |
| Year/Month | 2023 / 5 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Point] ●免疫チェックポイント阻害療法は弱体化したT細胞を活性化させ, 平衡相に近いT細胞免疫へと回復させることを目論見としている. ●平衡相に近いT細胞免疫への回復は, 生存曲線のテールプラトーで示されるユニークな長期生存効果を生む. ●進行期肺がんのみならず, 局所進行肺がんの化学放射線治療後, 肺がん周術期にも適応拡大されている. ●PD-1阻害薬に対する細胞傷害性抗がん薬併用は短期的な効果にとどまり全生存期間の改善にはつながらない. ●PD-1阻害薬単剤で不十分な効果となるPD-L1陰性肺がんでは, 抗CTLA-4抗体薬併用により上乗せ効果が得られる. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Dunn GP, et al : The three Es of cancer immunoediting. Annu Rev Immunol, 22 : 329-360, 2004
- 2) Borghaei H, et al : Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med, 373 : 1627-1639, 2015
- 3) Brahmer J, et al : Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, 373 : 123-135, 2015
- 4) Reck M, et al ; KEYNOTE-024 Investigators : Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 375 : 1823-1833, 2016
- 5) Reck M, et al : Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50. J Clin Oncol, 39 : 2339-2349, 2021
残りの16件を表示する
- 6) Mok TSK, et al ; KEYNOTE-042 Investigators : Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042) : a randomised, open-label, controlled, phase 3 trial. Lancet, 393 : 1819-1830, 2019
- 7) Gandhi L, et al ; KEYNOTE-189 Investigators : Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med, 378 : 2078-2092, 2018
- 8) Rodriguez-Abreu D, et al : Pemetrexed plus platinum with or without pembrolizumab in patients with previously un-treated metastatic nonsquamous NSCLC : protocol-specified final analysis from KEYNOTE-189. Ann Oncol, 32 : 881-895, 2021
- 9) Socinski MA, et al ; IMpower150 Study Group : Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med, 378 : 2288-2301, 2018
- 10) Reck M, et al ; IMpower150 Study Group : Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer(IMpower150) : key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med, 7 : 387-401, 2019
- 11) Paz-Ares L, et al ; KEYNOTE-407 Investigators : Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med, 379 : 2040-2051, 2018
- 12) Paz-Ares, L et al : A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC : Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol, 15 : 1657-1669, 2020
- 13) Garassino, M. C et al : KEYNNOTE-189 5-Year Update : First-line Pembrolizumab + Pemetrexed and Platinum vs Placebo + Pemetrexed and Platinum for Metastatic Nonsquamous NSCLC. Ann Oncol, 33(suppl7) : S448-S554, 2022
- 14) Novello S, et al : Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer : 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol, JCO2201990, 2023
- 15) Perol M, et al : Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line(1L)non-squamous non-small-cell lung cancer(Nsq-NSCLC)with PD-L1-high expression using real-world data. Ann Oncol, 33 : 511-521, 2022
- 16) Akinboro O, et al : FDA Approval Summary : Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC. Clin Cancer Res, 28 : 2221-2228, 2022
- 17) Hong L, et al : Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun, 14 : 695, 2023
- 18) Hellmann MD, et al : Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 381 : 2020-2031, 2019
- 19) Paz-Ares L, et al : First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer(CheckMate 9LA) : an inter-national, randomised, open-label, phase 3 trial. Lancet Oncol, 22 : 198-211, 2021
- 20) Johnson ML, et al ; POSEIDON investigators : Durvalumab With or Without Tremelimumab in Combination With Chemo-therapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer : The Phase III POSEIDON Study. J Clin Oncol, 41 : 1213-1227, 2023
- 21) Spigel DR, et al : Five-Year Survival Outcomes From the PACIFIC Trial : Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol, 40 : 1301-1311, 2022
